Twist Bioscience (NASDAQ:TWST) Shares Gap Down - What's Next?

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $52.37, but opened at $45.30. Twist Bioscience shares last traded at $49.24, with a volume of 362,146 shares.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target for the company. Finally, Scotiabank raised their price objective on Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.80.

Twist Bioscience Price Performance

The business has a fifty day moving average price of $48.84 and a two-hundred day moving average price of $46.32. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.92 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The firm's revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.75) earnings per share. On average, research analysts predict that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Patrick John Finn sold 10,340 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the sale, the chief operating officer now owns 221,061 shares of the company's stock, valued at approximately $10,610,928. This represents a 4.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 7,968 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $382,464.00. Following the completion of the sale, the chief executive officer now owns 581,584 shares of the company's stock, valued at approximately $27,916,032. The trade was a 1.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,002 shares of company stock worth $2,851,681. Company insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience in the third quarter valued at approximately $34,000. Van ECK Associates Corp lifted its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. US Bancorp DE increased its position in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience in the 3rd quarter valued at about $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.